首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   20333篇
  免费   1654篇
  国内免费   649篇
耳鼻咽喉   39篇
儿科学   216篇
妇产科学   140篇
基础医学   834篇
口腔科学   140篇
临床医学   1480篇
内科学   2516篇
皮肤病学   276篇
神经病学   1872篇
特种医学   199篇
外国民族医学   1篇
外科学   745篇
综合类   2227篇
一般理论   3篇
预防医学   1158篇
眼科学   152篇
药学   8695篇
  6篇
中国医学   1259篇
肿瘤学   678篇
  2024年   43篇
  2023年   319篇
  2022年   420篇
  2021年   685篇
  2020年   666篇
  2019年   756篇
  2018年   765篇
  2017年   825篇
  2016年   724篇
  2015年   719篇
  2014年   1446篇
  2013年   2205篇
  2012年   1308篇
  2011年   1375篇
  2010年   1103篇
  2009年   906篇
  2008年   853篇
  2007年   883篇
  2006年   730篇
  2005年   655篇
  2004年   544篇
  2003年   532篇
  2002年   378篇
  2001年   363篇
  2000年   282篇
  1999年   240篇
  1998年   223篇
  1997年   215篇
  1996年   212篇
  1995年   187篇
  1994年   155篇
  1993年   187篇
  1992年   182篇
  1991年   137篇
  1990年   131篇
  1989年   106篇
  1988年   116篇
  1987年   75篇
  1986年   87篇
  1985年   127篇
  1984年   113篇
  1983年   82篇
  1982年   92篇
  1981年   61篇
  1980年   70篇
  1979年   55篇
  1978年   63篇
  1977年   56篇
  1976年   47篇
  1975年   43篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
Although non-steroidal anti-inflammatory drug-induced colopathy is well described, colonic perforations complicating non-steroidal anti-inflammatory drug intake are rare. We report a patient with rheumatoid arthritis who was on long-term diclofenac and presented with early colonic stricture formation and a caecal perforation, which to the best of our knowledge, has only been reported once before. It is important to suspect this diagnosis in patients on non-steroidal anti-inflammatory drug therapy who present with an acute abdomen.  相似文献   
52.
溃疡散预防消化性溃疡复发临床观察   总被引:4,自引:0,他引:4  
目的 :观察溃疡散对消化性溃疡的抗复发治疗的临床效果。方法 :随机将 80例患者分成溃疡散治疗组 (4 2例 )和雷尼替丁对照组 (38例 )并同时观察两组患者治疗前后溃疡复发情况。结果 :治疗后治疗组溃疡复发率明显低于对照组 ,P <0 .0 1,两组对比有非常显著性差异。结论 :治疗组能明显的改善患者临床症状和降低消化性溃疡复发率。  相似文献   
53.
Although cardiac arrhythmias remain a serious clinical problem in many patients with heart disease, the exact role of antiarrhythmic drug therapy is currently under intense evaluation. Within the last several years it has become clear that there are significant risks as well as potential benefits associated with existing agents. Ongoing studies in large patient populations should help determine the benefit/risk ratio of traditional therapy. Regardless of the outcome of these trials, current electrophysiological dogma will have to be re-evaluated and newer concepts evolve for drug development to make further progress. The goal of this symposium is to exchange information among basic and clinical investigators so as to facilitate the emergence of novel electrophysiological concepts that will form the basis for future generations of antiarrhythmic drugs.  相似文献   
54.
Antihypertensive drugs are commonly associated with adverse side effects in both clinical and laboratory studies. We investigated the sexual sequelae of several major classes of antihypertensive drugs (e.g., beta blockers, central alpha agonists, diuretics) in normal males and in hypertensive patients. We compared the effects of four widely used agents (methyldopa, propranolol, atenolol, hydrochlorothiazide-triamterene) and placebo, in a selected sample of 21 sexually dysfunctional male hypertensives, 13 of whom completed all five phases of the study. Each study drug was administered for a 1-month treatment period, followed by a 2-week, single-blind washout phase, according to a randomized, Latin square crossover design. Dependent variables for the study included a broad range of hormonal, NPT, and self-report measures of sexual response. Results indicated a lack of consistent drug effects on measures of sexual response, although more frequent sexual and nonsexual side effects were observed with methyldopa and propranolol. As in our previous studies, age was negatively correlated with both hormonal and NPT measures, whereas changes in blood pressure were not significantly related to sexual function scores. Results do not support the hypothesis that sexually dysfunctional males are at greater risk for adverse sexual sequelae when treated with centrally active agents or diuretics.  相似文献   
55.
取代四氢异喹啉衍生物的合成及其生物活性   总被引:7,自引:0,他引:7  
粉防己碱有钙拮抗作用,临床试用于治疗高血压,其裂解产物钙拮抗作用降低,但有α-肾上腺素能受体拮抗作用,本文以裂解物为先导化合物设计合成了两类取代的四氢异喹啉衍生物Ⅲ及Ⅳ。初步药理试验表明:大部分化合物有α-肾上腺素能受体拮抗作用,少数化合物钙拮抗活性有所增强,其中Ⅲ15,19对正常麻醉大鼠有一定的降压作用、Ⅳ17,19对实验性动物心律失常有明显的保护作用。部分化合物量化计算表明:化合物与α1-受体作用方式可能是形成电荷转移复合物。  相似文献   
56.
Amiodarone hydrochloride is a potent antiarrhythmic agent recently approved for use by the Food and Drug Administration. Anterior subcapsular lens opacities were observed in seven of fourteen patients treated with moderate to high doses of amiodarone at the Veterans Administration Medical Center in San Francisco in 1982. The present report summarizes the present status of these same fourteen patients ten years later. Anterior subcapsular lens opacities developed or progressed in all patients continuing treatment with this antiarrhythmic agent during the following ten year interval. Although Snellen visual acuities are not decreased, subtle visual impairment is present as measured by contrast sensitivity measurements with and without glare. This decrease in visual acuity is not a contraindication for therapy with this potentially life saving drug.  相似文献   
57.
初步分析了11例外伤性截瘫合并耳聋患者,指出外伤性截瘫多有慢性肾功能不全、肾性贫血等并发症。这些并发症对耳聋的发生有一定的影响,但长时间或反复使用耳毒性药物是一个不可忽视的重要因素。作者对此提出了预防耳聋的一些具体措施,可供临床参考或借鉴。  相似文献   
58.
本实验以荷 Lewis 肺癌的 NIH 小鼠为模型,以肿瘤平均直径倍增时间(MDDT)为终点,进行加温合并抗癌药物的研究。结果表明:①43℃加温25分钟,对 Lewis 肺癌有明显的治疗效果(P<0.05);②喜树碱16mg/kg合并加温25分钟,对 Lewis 肺癌的抑制作用随加热温度升高而加强,在43℃时出现相加作用(P<0.001);③斑蝥素0.45mg/kg,高三尖杉酯碱1.2mg/kg 或消瘤芥0.75mg/kg 合并加温25分钟,对Lewis 肺癌的抑制作用随加热温度升高而增强,其中斑蝥素和消瘤芥在43℃时出现协同作用(P<0.001);①去甲斑蝥酸钠3mg/kg 对 Lewis 肺癌无治疗作用,但合并43℃加温25分钟时有协同作用;⑤鸦胆子油口服乳液8ml/kg,间隔27小时合并43℃加温25分钟,对 Lewis 肺癌的治疗有相加作用,并明显延长了荷瘤动物的生存时间。  相似文献   
59.
The XIVth World Congress of Pharmacology took place July 7–12, 2002 in Moscone Convention Center, San Francisco, CA. Over 4,000 scientists, exhibitors and guests attended the Congress. It consisted of 40 symposia, 11 workshops, 18 plenary lectures and ca. 1,400 posters. The Congress was sponsored by the American Society for Pharmacology and Experimental Therapeutics, Inspire Pharmaceuticals and GlaxoSmithKline. The major financial donors were: Eli Lilly and Company, Servier, Johnson & Johnson, Merck, Novartis, Roche, Schering‐Plough, Wyeth and Yamanouchi Foundation. This report covers only presentations and posters on drugs that were attended or viewed by the author.  相似文献   
60.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号